Pulmonary Diseases

Natural autoantibodies (NAAs) are thought to have a variety of physiological roles, including first line of defence against infection, clearance of ageing cells and their constituents, antigen presentation, anti-tumour and anti-inflammatory activities and immune homeostasis. Creative Biolabs provides customized NAA services against various autoantigens for different pulmonary diseases aided by advanced technology platform to help your projects. Our professional scientists have extensive experience in antibody analysis, and disease diagnosis in vivo and in vitro. We are committed to providing high-quality services to promote the development of NAA research.

Pulmonary Diseases and Natural Autoantibodies

Pathogenic autoantibodies directly target secreted or membrane-associated autoantigens to cause diseases mainly by disrupting the function of target proteins or by promoting the destruction of cells expressing these cell-surface molecules. In the past decade, many new pathogenic autoantibodies have been identified in pulmonary diseases. Autoantibody subsets are associated with different patterns of pulmonary disease. The most widely reported are Pulmonary Alveolar Proteinosis (PAP) and interstitial lung disease (ILD). PAP is a rare syndrome characterized by the accumulation of surfactant in alveoli and terminal airways resulting in respiratory failure and ILD is a group of lung disorders affecting the tissue and space around the air sacs and it is an important manifestation of connective tissue diseases (CTD).

Fig.1 The aPAP development. (Lund-Palau, et al., 2022)Fig.1 Pathophysiology of aPAP.1

The Importance of Natural Autoantibodies

Polymyositis and dermatomyositis (PM/DM) are systemic autoimmune disorders that involve muscle, skin and lungs. In PM/DM patients, the presence of serum myositis-specific autoantibody is a key finding for diagnosis and classification. A number of autoantibodies are detected in PM/DM patients sera, some of which are specific to PM/DM (known as myositis specific autoantibodies; MSAs) or myositis overlap syndromes (known as myositis-associated autoantibodies, MAAs). Obviously, each MSA/MAA has characteristic clinical significance, being closely associated with symptoms, complications, reactivity to therapy or prognosis of PM/DM patients. Thus, identification and measurement of MSAs/MAAs can aid the diagnosis, classification and management of PM/DM patients.

Suggested algorithm for assessment of ILD and autoantibody testing. Fig.2 Suggested algorithm for assessment of ILD and autoantibody testing. (Jee, 2017)

Autoantibodies assessment is a part of differential diagnosis algorithm of pulmonary diseases. Autoantibodies is important for clinical-diagnostic of pulmonary diseases. Detection of some autoantibodies is possible to determine prognosis of lung involvement, especially in CTDs. It is well recognized that CTD-related autoantibodies are associated with specific clinical features. The identification of CTD-related autoantibodies is clinically important, since they are closely associated with distinct clinical symptoms and are predictive factors for prognosis. For instance, anti-topo I Ab, anti-Th/To Ab, anti-U11/U12 RNP Ab, anti-ARS Ab, and anti-MDA5 Ab and anti-GMCSF Ab are strongly associated with ILD and PAP respectively.

Technologies and Advantages of Creative Biolabs

Autoimmunity may contribute to the pathogenesis of different chronic pulmonary diseases and autoantibodies may be used as early biomarkers for diseases detection and prevention. With novel technology platform and professional experiment services, Creative Biolabs gets ready to provide you with the best NAA detection and analysis services. If the disease you concerned is not mentioned above, please feel free to contact us for more details.

References

  1. Lund-Palau, Helena, et al. "Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression." Molecular Therapy-Methods & Clinical Development 25 (2022): 382-391.
  2. Jee, Adelle S., et al. "Role of autoantibodies in the diagnosis of connective-tissue disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF)." Journal of clinical medicine 6.5 (2017): 51.

Choosing natural autoantibody (NAA) microarray to profile autoantibody repertoire and reveal novel disease's marker.

For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry